Use of posaconazole delayed-release tablets for treatment of invasive aspergillosis.
A 65-year-old man developed Aspergillus brain abscesses following surgical resection of a sinus aspergilloma. He was treated with voriconazole for 1 year but infection recurred. We elected to treat with posaconazole delayed-release tablets, currently only indicated as antifungal prophylaxis in high-risk patients. A maintenance dose of 300 mg Q24 h resulted in a therapeutic serum concentration and appears safe and clinically effective thus far. This is the first report of successful use of posaconazole tablets for treatment of invasive aspergillosis.
Division of Infectious Diseases, Rush University Medical Center, Chicago, IL, USA.
Marjorie M
MM
Conant
Beverly E
BE
Sha
Laurie A
LA
Proia
D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000097:blood; D001921:Brain / Q000382:microbiology; D001922:Brain Abscess / Q000188:drug therapy*; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D006801:Humans; D008297:Male; D020953:Neuroaspergillosis / Q000188:drug therapy*; D013607:Tablets; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage* / Q000097:blood; D065819:Voriconazole / Q000627:therapeutic use
D000935:Antifungal Agents; D003692:Delayed-Action Preparations; D013607:Tablets; D014230:Triazoles; C101425:posaconazole; D065819:Voriconazole
Posaconazole; antifungal therapy; aspergillus; invasive mould infection